ArticleBMC infectious diseases2025
Prevalence, associated factors, and viral load dynamics of hepatitis B virus infection among HIV patients in three healthcare facilities of South Kivu province, eastern Democratic Republic of Congo : Chronic hepatitis B virus among HIV patients in South Kivu province.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundHepatitis B virus (HBV) significantly impacts public health, particularly among individuals with Human Immunodeficiency Virus (HIV). Co-infection can worsen HBV progression and increase chronic liver disease risks. This study assessed HBV marker frequency, viral load (VL), and associated factors in HIV patients in South Kivu province (Democratic Republic of Congo) to understand the health implications of HBV-HIV co-infection.
methodsThis cross-sectional study, from July 1, 2019, to July 30, 2021, included 864 HIV patients aged 18 to 70 years from General Referral Hospital of Panzi (GRH Panzi), Regional Military Hospital of Bukavu (RMH Bukavu), and Fomulac Hospital. Participants, on antiretroviral therapy, ART (TDF/3TC/DTG or AZT/3TC/LPV/r combinations) or newly diagnosed, consented for blood testing for hepatitis B using enzyme-linked immunosorbent assay (ELISA) and VLs using GeneXpert. Data were analyzed with Stata SE 14.0.
resultsThe study found 8.0% HBsAg positivity among HIV patients in South Kivu, with 41.3% and 14.1% showing Anti-HBc and Anti-HBs, respectively. HBsAg positivity was linked to male gender (AOR = 2.96; p = 0.007), rural origin (AOR = 4.32; p = 0.014), treatment at Fomulac Hospital (AOR = 4.87; p = 0.002), marital status (AOR = 4.55; p = 0.036), lower education (AOR = 57.25; p = 0.002), jaundice history (AOR = 3.98; p = 0.021), and < 5 years of unprotected sex (AOR = 10.96; p = 0.002). The HIV VL average was 3.26 ± 3.57 log
conclusionHigh HBV co-infection rates in HIV-positive individuals in South Kivu necessitate regular HBV monitoring including prevention, screening, and vaccination strategies in HIV care. Despite ART managing both infections effectively, further research on HBV-related outcomes is essential for improving co-infected patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.